Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Sep;85(6):823–826. doi: 10.1054/bjoc.2001.2006

Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis

M von Schlippe 1, C J Fowler 2, S J Harland 1,2
PMCID: PMC2375074  PMID: 11556831

Abstract

In order to ascertain the incidence and prognosis of cisplatin-induced neurotoxicity in testis cancer patients undergoing combination chemotherapy, 29 patients with metastatic disease were studied prospectively. Assessments included enquiry into neurological symptoms, measurement of sural nerve sensory action potential and conduction velocity, and vibration threshold in the left big toe. At the end of chemotherapy (3 to 4 cycles) only 3 out of 26 (11%) patients had paraesthesiae, but 3 months later the proportion rose to 65%. Resolution occurred in the majority over the ensuing 12 months so that only 17% had persistent symptoms. None of the 11 patients treated with 3 cycles of chemotherapy had persisting symptoms. Vibration thresholds showed a significant deterioration during chemotherapy (P = 0.032), further deterioration in the 3 months following chemotherapy (P = 0.009) and significant improvement between 3 and 12 months after chemotherapy (P = 0.038). Sural nerve sensory action potentials and conduction velocities were unhelpful.© 2001 Cancer Research Campaignhttp://www.bjcancer.com

Full Text

The Full Text of this article is available as a PDF (199.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashraf M., Scotchel P. L., Krall J. M., Flink E. B. cis-Platinum-induced hypomagnesemia and peripheral neuropathy. Gynecol Oncol. 1983 Dec;16(3):309–318. doi: 10.1016/0090-8258(83)90156-7. [DOI] [PubMed] [Google Scholar]
  2. Berger T., Malayeri R., Doppelbauer A., Krajnik G., Huber H., Auff E., Pirker R. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer. 1997 Aug;33(9):1393–1399. doi: 10.1016/s0959-8049(97)00103-2. [DOI] [PubMed] [Google Scholar]
  3. Bokemeyer C., Berger C. C., Kuczyk M. A., Schmoll H. J. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol. 1996 Nov;14(11):2923–2932. doi: 10.1200/JCO.1996.14.11.2923. [DOI] [PubMed] [Google Scholar]
  4. Cavaletti G., Bogliun G., Marzorati L., Tredici G., Colombo N., Parma G., Miceli M. D. Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. Anticancer Res. 1994 May-Jun;14(3B):1287–1292. [PubMed] [Google Scholar]
  5. Cavaletti G., Marzorati L., Bogliun G., Colombo N., Marzola M., Pittelli M. R., Tredici G. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer. 1992 Jan 1;69(1):203–207. doi: 10.1002/1097-0142(19920101)69:1<203::aid-cncr2820690133>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  6. Daugaard G. K., Petrera J., Trojaborg W. Electrophysiological study of the peripheral and central neurotoxic effect of cis-platin. Acta Neurol Scand. 1987 Aug;76(2):86–93. doi: 10.1111/j.1600-0404.1987.tb03551.x. [DOI] [PubMed] [Google Scholar]
  7. DiBenedetto M. Sensory nerve conduction in lower extremities. Arch Phys Med Rehabil. 1970 May;51(5):253–passim. [PubMed] [Google Scholar]
  8. Einhorn L. H., Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977 Sep;87(3):293–298. doi: 10.7326/0003-4819-87-3-293. [DOI] [PubMed] [Google Scholar]
  9. Einhorn L. H., Williams S. D. Chemotherapy of disseminated testicular cancer. A random prospective study. Cancer. 1980 Sep 15;46(6):1339–1344. doi: 10.1002/1097-0142(19800915)46:6<1339::aid-cncr2820460607>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  10. Einhorn L. H., Williams S. D., Loehrer P. J., Birch R., Drasga R., Omura G., Greco F. A. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol. 1989 Mar;7(3):387–391. doi: 10.1200/JCO.1989.7.3.387. [DOI] [PubMed] [Google Scholar]
  11. Foster-Nora J. A., Siden R. Amifostine for protection from antineoplastic drug toxicity. Am J Health Syst Pharm. 1997 Apr 1;54(7):787–800. doi: 10.1093/ajhp/54.7.787. [DOI] [PubMed] [Google Scholar]
  12. Grunberg S. M., Sonka S., Stevenson L. L., Muggia F. M. Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemother Pharmacol. 1989;25(1):62–64. doi: 10.1007/BF00694340. [DOI] [PubMed] [Google Scholar]
  13. Hardaker W. T., Jr, Stone R. A., McCoy R. Platinum nephrotoxicity. Cancer. 1974 Oct;34(4):1030–1032. doi: 10.1002/1097-0142(197410)34:4<1030::aid-cncr2820340411>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  14. Hilkens P. H., Pronk L. C., Verweij J., Vecht C. J., van Putten W. L., van den Bent M. J. Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer. 1997;75(3):417–422. doi: 10.1038/bjc.1997.68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hilkens P. H., van der Burg M. E., Moll J. W., Planting A. S., van Putten W. L., Vecht C. J., van den Bent M. J. Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration. Eur J Cancer. 1995;31A(5):678–681. doi: 10.1016/0959-8049(94)00497-s. [DOI] [PubMed] [Google Scholar]
  16. Kaye S. B., Mead G. M., Fossa S., Cullen M., deWit R., Bodrogi I., van Groeningen C., Sylvester R., Collette L., Stenning S. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol. 1998 Feb;16(2):692–701. doi: 10.1200/JCO.1998.16.2.692. [DOI] [PubMed] [Google Scholar]
  17. Kedar A., Cohen M. E., Freeman A. I. Peripheral neuropathy as a complication of cis-dichlorodiammineplatinum(II) treatment: a case report. Cancer Treat Rep. 1978 May;62(5):819–821. [PubMed] [Google Scholar]
  18. Le Quesne P. M., Fowler C. J. Quantitative evaluation of toxic neuropathies in man. Electroencephalogr Clin Neurophysiol Suppl. 1987;39:347–354. [PubMed] [Google Scholar]
  19. Mollman J. E., Hogan W. M., Glover D. J., McCluskey L. F. Unusual presentation of cis-platinum neuropathy. Neurology. 1988 Mar;38(3):488–490. doi: 10.1212/wnl.38.3.488. [DOI] [PubMed] [Google Scholar]
  20. Nielsen V. K. The peripheral nerve function in chronic renal failure. IV. An analysis of the vibratory perception threshold. Acta Med Scand. 1972 Apr;191(4):287–296. [PubMed] [Google Scholar]
  21. Planting A. S., Catimel G., de Mulder P. H., de Graeff A., Höppener F., Verweij J., Oster W., Vermorken J. B. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. Ann Oncol. 1999 Jun;10(6):693–700. doi: 10.1023/a:1008353505916. [DOI] [PubMed] [Google Scholar]
  22. Riggs J. E., Ashraf M., Snyder R. D., Gutmann L. Prospective nerve conduction studies in cisplatin therapy. Ann Neurol. 1988 Jan;23(1):92–94. doi: 10.1002/ana.410230116. [DOI] [PubMed] [Google Scholar]
  23. STEINESS I. Vibratory perception in diabetics; a biothesiometric study. Acta Med Scand. 1957 Sep 20;158(5):327–335. doi: 10.1111/j.0954-6820.1957.tb15497.x. [DOI] [PubMed] [Google Scholar]
  24. STEINESS I. Vibratory perception in normal subjects; a biothesiometric study. Acta Med Scand. 1957 Sep 20;158(5):315–325. doi: 10.1111/j.0954-6820.1957.tb15496.x. [DOI] [PubMed] [Google Scholar]
  25. de Wit R., Roberts J. T., Wilkinson P. M., de Mulder P. H., Mead G. M., Fosså S. D., Cook P., de Prijck L., Stenning S., Collette L. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001 Mar 15;19(6):1629–1640. doi: 10.1200/JCO.2001.19.6.1629. [DOI] [PubMed] [Google Scholar]
  26. van der Hoop R. G., Vecht C. J., van der Burg M. E., Elderson A., Boogerd W., Heimans J. J., Vries E. P., van Houwelingen J. C., Jennekens F. G., Gispen W. H. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med. 1990 Jan 11;322(2):89–94. doi: 10.1056/NEJM199001113220204. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES